Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy.
Kifjak D, Hochmair M, Sobotka D, Haug AR, Ambros R, Prayer F, Heidinger BH, Roehrich S, Milos RI, Wadsak W, Fuereder T, Krenbek D, Fazekas A, Meilinger M, Mayerhoefer ME, Langs G, Herold C, Prosch H, Beer L. Kifjak D, et al. Among authors: hochmair m. Eur J Radiol. 2024 Jan;170:111198. doi: 10.1016/j.ejrad.2023.111198. Epub 2023 Nov 21. Eur J Radiol. 2024. PMID: 37992608 Free article.
Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.
Kifjak D, Hochmair MJ, Krenbek D, Milos RI, Heidinger BH, Prayer F, Röhrich S, Watzenboeck ML, Oberndorfer F, Klikovits T, Aigner C, Sinn K, Hoda MA, Hoetzenecker K, Haug AR, Prosch H, Beer L. Kifjak D, et al. Eur J Radiol. 2023 Apr;161:110732. doi: 10.1016/j.ejrad.2023.110732. Epub 2023 Feb 8. Eur J Radiol. 2023. PMID: 36804313 Free article. Review.
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R; European EGFR Workshop Group. Pirker R, et al. J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de. J Thorac Oncol. 2010. PMID: 20871269 Free article.
Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Sztankay M, Giesinger JM, Zabernigg A, Krempler E, Pall G, Hilbe W, Burghuber O, Hochmair M, Rumpold G, Doering S, Holzner B. Sztankay M, et al. Among authors: hochmair m. BMC Cancer. 2017 Aug 23;17(1):565. doi: 10.1186/s12885-017-3543-7. BMC Cancer. 2017. PMID: 28835219 Free PMC article.
Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
Schwarz M, Kocher F, Niedersuess-Beke D, Rudzki J, Hochmair M, Widmann G, Hilbe W, Pircher A. Schwarz M, et al. Among authors: hochmair m. Clin Lung Cancer. 2019 May;20(3):e247-e250. doi: 10.1016/j.cllc.2018.12.006. Epub 2018 Dec 19. Clin Lung Cancer. 2019. PMID: 30635258 No abstract available.
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).
Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E. Halmos B, et al. Among authors: hochmair m. Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2. Lung Cancer. 2019. PMID: 30642537 Free article.
142 results